ProfessorSianHarding

Faculty of Medicine, National Heart & Lung Institute

Professor of Cardiac Pharmacology

Contact

Location

435ICTEM buildingHammersmith Campus

Summary

Sian Harding is Professor of Cardiac Pharmacology at the National Heart and Lung Institute, Imperial College London, and a co-investigator within the UKRMP Immunomodulation Hub.

She obtained her Ph.D. in Pharmacology from King's College, London in 1981, and since then the primary focus of her work has been cardiomyocyte function in the failing heart. This has extended to gene therapy to modulate cardiomyocyte function, and she is Scientific PI for the UK's first clinical trial on myocardial gene therapy. More recently the scope has extended to the characterisation of cardiomyocytes derived from embryonic stem cells, and their use in cardiac repair, tissue engineering and drug discovery.

Professor Harding is Past-President of the European Section of the International Society for Heart Research and Fellow of the AHA, ESC and ISHR. She sits on the Nuffield Council on Bioethics and the Scientific Advisory Board of the PPP "Stem Cells for Safer Medicines".

Professor Harding delivered her Inaugural Lecture, entitled 'Reviving the Failing Heart: one cell at a time', on 3 April 2007. The abstract and other details of the lecture can be found here.

Publications

Journals

Hellen N, Pinto Ricardo C, Vauchez K, et al.Hellen N, Pinto Ricardo C, Vauchez K, Whiting G, Wheeler JX, Harding SE close, 2019, Proteomic Analysis Reveals Temporal Changes in Protein Expression in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes In Vitro., Stem Cells Dev

Fiedler LR, Chapman K, Xie M, et al.Fiedler LR, Chapman K, Xie M, Maifoshie E, Jenkins M, Golforoush PA, Bellahcene M, Noseda M, Faust D, Jarvis A, Newton G, Paiva MA, Harada M, Stuckey DJ, Song W, Habib J, Narasimham P, Aqil R, Sanmugalingam D, Yan R, Pavanello L, Sano M, Wang SC, Sampson RD, Kanayaganam S, Taffet GE, Michael LH, Entman ML, Tan T-H, Harding SE, Low CMR, Tralau-Stewart C, Perrior T, Schneider MD close, 2019, MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo., Cell Stem Cell

Shun-Shin MJ, Leong KMW, Ng FS, et al.Shun-Shin MJ, Leong KMW, Ng FS, Linton NWF, Whinnett ZI, Koa-Wing M, Qureshi N, Lefroy DC, Harding SE, Lim PB, Peters NS, Francis DP, Varnava AM, Kanagaratnam P close, 2019, Ventricular conduction stability test: a method to identify and quantify changes in whole heart activation patterns during physiological stress., Europace

Sattler S, Couch LS, Harding SE, 2018, Takotsubo Syndrome: Latest Addition to the Expanding Family of Immune-Mediated Diseases?, Jacc Basic Transl Sci, Vol:3, Pages:779-781

Smith JGW, Owen T, Bhagwan JR, et al.Smith JGW, Owen T, Bhagwan JR, Mosqueira D, Scott E, Mannhardt I, Patel A, Barriales-Villa R, Monserrat L, Hansen A, Eschenhagen T, Harding SE, Marston S, Denning C close, 2018, Isogenic Pairs of hiPSC-CMs with Hypertrophic Cardiomyopathy/LVNC-Associated ACTCI E99K Mutation Unveil Differential Functional Deficits, Stem Cell Reports, Vol:11, ISSN:2213-6711, Pages:1226-1243

More Publications